Gastrointestinal motility enhancement via laxative effect

Gastrointestinal motility enhancement via laxative effect" is not the name of a specific molecule or receptor but rather describes a **physiological process** involving the stimulation of gut movement, often targeted therapeutically in conditions like constipation. This process can be modulated by several molecular targets including serotonin receptors—especially **5-hydroxytryptamine 4 (5‑HT₄) receptors**, which are G protein-coupled receptors that mediate excitatory neurotransmission in the enteric nervous system—and **motilin receptors**, which regulate gastric contractions. Drugs such as erythromycin act as motilin receptor agonists, while mosapride and tegaserod are examples of 5‑HT₄ receptor agonists used clinically for their prokinetic effects. The underlying mechanisms may also involve modulation of ion channels leading to increased intestinal secretion, further promoting transit. Because this entry does not refer to a single defined molecular entity but rather an outcome or therapeutic goal achieved through multiple possible targets, it is not considered an appropriate "therapeutic target" under standard nomenclature conventions.[1][2][3]

Agonism of 5-hydroxytryptamine 4 (5-HT4) receptors to stimulate peristalsis and enhance gut motility[1][3] Agonism of motilin receptors to increase gastric contractions and accelerate gastric emptying[3] Modulation of ion channels and exchangers in epithelial cells to promote intestinal secretion and transit[1]